Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.

McGuire DK, See R, Abdullah SM, Snell PG, McGavock JM, Ayers CR, Szczepaniak LS.

Diab Vasc Dis Res. 2009 Jan;6(1):43-50. doi: 10.3132/dvdr.2009.009.


Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.

McGuire DK, Abdullah SM, See R, Snell PG, McGavock J, Szczepaniak LS, Ayers CR, Drazner MH, Khera A, de Lemos JA.

Eur Heart J. 2010 Sep;31(18):2262-70. doi: 10.1093/eurheartj/ehq228. Epub 2010 Jul 2.


Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment.

Narang N, Armstead SI, Stream A, Abdullah SM, See R, Snell PG, McGavock J, Ayers CR, Gore MO, Khera A, de Lemos JA, McGuire DK.

Diab Vasc Dis Res. 2011 Apr;8(2):101-8. doi: 10.1177/1479164111403334.


The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: a randomised, placebo-controlled trial.

McGavock J, Szczepaniak LS, Ayers CR, Abdullah SM, See R, Gore MO, Drazner MH, de Lemos JA, McGuire DK.

Diab Vasc Dis Res. 2012 Apr;9(2):131-7. doi: 10.1177/1479164111428628. Epub 2011 Nov 8.


Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.

van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M.

Circulation. 2009 Apr 21;119(15):2069-77. doi: 10.1161/CIRCULATIONAHA.108.803916. Epub 2009 Apr 6.


Rosiglitazone improves exercise capacity in individuals with type 2 diabetes.

Regensteiner JG, Bauer TA, Reusch JE.

Diabetes Care. 2005 Dec;28(12):2877-83.


Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes--update 2008.

Rohatgi A, McGuire DK.

Cardiovasc Drugs Ther. 2008 Jun;22(3):233-40. doi: 10.1007/s10557-008-6093-z. Epub 2008 Mar 29. Review.


Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.


Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.

Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, Ramachandran A, Riddle M, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein H; TIDE Trial Investigators.

Diabetologia. 2012 Jan;55(1):36-45. doi: 10.1007/s00125-011-2357-4. Epub 2011 Oct 29.


Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.


Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group.

Am Heart J. 2008 Dec;156(6):1074-9. doi: 10.1016/j.ahj.2008.07.025. Epub 2008 Oct 11.


Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus.

Türkmen Kemal Y, Güvener Demirag N, Yildirir A, Atar A, Dogruk Unal A, Biyiklioglu Z.

Acta Diabetol. 2007 Sep;44(3):149-56. Epub 2007 Aug 26.


A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Bertrand OF, Poirier P, Rodés-Cabau J, Rinfret S, Title L, Dzavik V, Natarajan M, Angel J, Batalla N, Alméras N, Costerousse O, De Larochellière R, Roy L, Després JP; VICTORY trial investigators.

Can J Cardiol. 2009 Sep;25(9):509-15.


Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.


Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

Patel C, Wyne KL, McGuire DK.

Diab Vasc Dis Res. 2005 May;2(2):61-6. Review.


Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice.

How OJ, Larsen TS, Hafstad AD, Khalid A, Myhre ES, Murray AJ, Boardman NT, Cole M, Clarke K, Severson DL, Aasum E.

Arch Physiol Biochem. 2007 Oct-Dec;113(4-5):211-20.


Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes.

van Wijk JP, de Koning EJ, Castro Cabezas M, Rabelink TJ.

Diabetes Care. 2005 Apr;28(4):844-9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk